Absence of SV40 antibodies or DNA fragments in prediagnostic mesothelioma serum samples

被引:54
作者
Kjaerheim, Kristina [1 ]
Roe, Oluf Dimitri
Waterboer, Tim
Sehr, Peter
Rizk, Raeda
Dai, Hong Yan
Sandeck, Helmut
Larsson, Erik
Andersen, Aage
Boffetta, Paolo
Pawlita, Michael
机构
[1] Canc Registry Norway, Oslo, Norway
[2] St Olavs Univ Hosp, Dept Oncol, Trondheim, Norway
[3] NTNU, Dept Canc Res & Mol Med, Trondheim, Norway
[4] German Canc Res Ctr, DKFZ, Res Program Infect & Canc, D-6900 Heidelberg, Germany
[5] St Olavs Univ Hosp, Dept Pathol & Med Genet, Trondheim, Norway
[6] Norwegian Univ Sci & Technol, Dept Lab Med Childrens & Womens Hlth, N-7034 Trondheim, Norway
[7] Int Agcy Res Canc, F-69372 Lyon, France
关键词
polio vaccination; viral infection; simian virus 40; malignant mesothelioma;
D O I
10.1002/ijc.22592
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The rhesus monkey virus Simian Virus 40 (SV40) is a member of the polyomavirus family. It was introduced inadvertently to human populations through contaminated polio vaccine during the years 1956-1963, can induce experimental tumors in animals and transform human cells in culture. SV40 DNA has been identified in mesothelioma and other human tumors in some but not all studies. We tested prediagnostic sera from 49 mesothelioma cases and 147 matched controls for antibodies against the viral capsid protein VP1 and the large T antigen of SV40 and of the closely related human polyomaviruses BK and JC, and for SV40 DNA. Cases and controls were identified among donors to the Janus Serum Bank, which was linked to the Cancer Registry of Norway. Antibodies were analyzed by recently developed multiplex serology based on recombinantly expressed fusions of glutathione-S transferase with viral proteins as antigens combined with fluorescent bead technology. BKV and JCV specific antibodies cross-reactive with SV40 were preabsorbed with the respective VP1 proteins. Sera showing SV40 reactivity after preabsorption with BKV and JCV VP1 were further analyzed in SV40 neutralization assays. SV40 DNA was analyzed by SV40 specific polymerase chain reactions. The odds ratio for being a case when tested positive for SV40 VP1 in the antibody capture assay was 1.5 (95% CI 0.6-3.7) and 2.0 (95% CI 0.6-7.0) when only strongly reactive sera where counted as positive. Although some sera could neutralize SV40, preabsorption with BKV and JCV VP1 showed for all such sera that this neutralizing activity was due to cross-reacting antibodies and did not represent truly SV40-specific antibodies. No viral DNA was found in the sera. No significant association between SV40 antibody response in prediagnostic sera and risk of mesothelioma was seen. (c) 2007 Wiley-Liss, Inc.
引用
收藏
页码:2459 / 2465
页数:7
相关论文
共 53 条
[1]  
*ARB, 1965, NORD YRK
[2]   DNA-SEQUENCES SIMILAR TO THOSE OF SIMIAN VIRUS-40 IN EPENDYMOMAS AND CHOROID-PLEXUS TUMORS OF CHILDHOOD [J].
BERGSAGEL, DJ ;
FINEGOLD, MJ ;
BUTEL, JS ;
KUPSKY, WJ ;
GARCEA, RL .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (15) :988-993
[3]  
Bjorge T, 1997, CANCER RES, V57, P3989
[4]   Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers [J].
Bjorge, T ;
Dillner, J ;
Anttila, T ;
Engeland, A ;
Hakulinen, T ;
Jellum, E ;
Lehtinen, M ;
Luostarinen, T ;
Paavonen, J ;
Pukkala, E ;
Sapp, M ;
Schiller, J ;
Youngman, L ;
Thoresen, S .
BRITISH MEDICAL JOURNAL, 1997, 315 (7109) :646-649
[5]   B-LYMPHOTROPIC PAPOVAVIRUS AND POSSIBILITY OF INFECTIONS IN HUMANS [J].
BRADE, L ;
MULLERLANTZSCH, N ;
HAUSEN, HZ .
JOURNAL OF MEDICAL VIROLOGY, 1980, 6 (04) :301-308
[6]   An optimized battery of eight antibodies that can distinguish mast gases at epithelial mesothelioma from adenocarcinoma [J].
Brockstedt, U ;
Gulyas, M ;
Dobra, K ;
Dejmek, A ;
Hjerpe, A .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 114 (02) :203-209
[7]  
Butel J S, 2003, Cent Eur J Public Health, V11, P3
[8]  
CARBONE M, 1994, ONCOGENE, V9, P1781
[9]   Lack of serologic evidence for prevalent simian virus 40 infection in humans [J].
Carter, JJ ;
Madeleine, MM ;
Wipf, GC ;
Garcea, RL ;
Pipkin, PA ;
Minor, PD ;
Galloway, DA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (20) :1522-1530
[10]  
CHRUG A, 2004, PATHOLOGY GENETICS T, P128